Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
Status:
Terminated
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol
Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol
Topical Oil is applied to pediatric subjects with moderate to severe atopic dermatitis (AD)
under maximal use conditions.
The study duration for each subject will be up to 54 days (up to 38 days for Screening
assessments, followed by up to 16 days of treatment and follow-up). Additional time will be
required for subjects requiring additional hypothalamic-pituitary-adrenal [HPA] axis function
testing due to an abnormal result at End of Treatment.